"first do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects

Journal of Psychopharmacology

Volumn 29, Issue 4, 2015, Pages 353-362

  Young, Su Ling ^a   Taylor, Mark ^b   Lawrie, Stephen M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL EDINBURGH HOSPITAL   (United Kingdom)

Author keywords

adverse effects; Antipsychotics; management; prevalence

Indexed keywords

AMISULPRIDE; ANTILIPEMIC AGENT; ARIPIPRAZOLE; CHOLESTEROL; CLOZAPINE; GLUCOSE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; AMENORRHEA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CATATONIA; CHOLESTEROL BLOOD LEVEL; DIET THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DYSLIPIDEMIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; GROUP THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPROLACTINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; META ANALYSIS (TOPIC); METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARKINSONISM; PHYSICAL ACTIVITY; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEDATION; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; FEMALE; MALE; MENTAL DISORDERS; SEVERITY OF ILLNESS INDEX;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 84924965507     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114562090     Document Type: Review

References (79)

1. Ahmer S, Khan RA, Iqbal SP. Association between antipsychotics and weight gain among psychiatric outpatients in Pakistan: A retrospective cohort study. Ann Gen Psychiatry. 2008 ; 7: 12
2. Ajetunmobi O, Taylor M, Stockton D, et al. Early death in those previously hospitalised for mental healthcare in Scotland: A nationwide cohort study, 1986-2010. BMJ Open. 2013 ; 3: e002768
3. Attux C, Martini LC, Araújo CM, et al. The effectiveness of a non-pharmacological intervention for weight gain management in severe mental disorders: Results from a national multicentric study. Rev Bras Psiquiatr. 2011 ; 33: 117-121
4. Bai YM, Chen TT, Yang WS, et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study. Schizophr Res. 2009 ; 111: 1-8
5. Bai YM, Lin CC, Chen JY, et al. Association of weight gain and metabolic syndrome in patients taking clozapine: An 8-year cohort study. J Clin Psychiatry. 2011 ; 72: 751-756
6. Banta JE, Morrato EH, Lee SW, et al. Retrospective analysis of diabetes care in California Medicaid patients with mental illness. J Gen Intern Med. 2009 ; 24: 802-808
7. Barak Y, Aizenberg D. Switching to aripiprazole as a strategy for weight reduction: A meta-analysis in patients suffering from schizophrenia. J Obes. 2011 2011 ; 898013 :
8. Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia: Benefits and risks. CNS Drugs. 2011 ; 25: 383-399
9. Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. J Sex Marital Ther. 2003 ; 29: 125-147
10. Brooks JO, Goldberg JF, Ketter TA, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: Findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry. 2011 ; 72: 240-247
11. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007 ; 21: 768-773
12. Bushe C, Yeomans D, Floyd T, et al. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol. 2008 ; 22: 56-62
13. Byne W, White L, Parella M, et al. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: Prevalence and association with cognitive impairment. Int J Geriatr Psychiatry. 1998 ; 13: 473-479
14. Chagnon YC, Bureau A, Gendron D, et al. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. Am J Med Genet B Neuropsychiatr Genet. 2007 ; 144: 1063-1069
15. Chong SA, Mythily, Remington G. Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia. Schizophr Res. 2003 ; 59: 67-71
16. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000 ; 342: 1887-1892
17. Curtis J, Henry C, Watkins A, et al. Metabolic abnormalities in an early psychosis service: A retrospective, naturalistic cross-sectional study. Early Interv Psychiatry. 2011 ; 5: 108-114
18. Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011 ; 94: 246-254
19. Falissard B, Mauri M, Shaw K, et al. The METEOR study: Frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol. 2011 ; 26: 291-302
20. Farooq S, Taylor M. Clozapine: Dangerous orphan or neglected friend?. Br J Psychiatry. 2011 ; 198: 247-249
21. Fernandez HH, Friedman JH, Lansang MC, et al. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Relat Disord. 2004 ; 10: 439-441
22. Fleischhacker WW, Meise U, Günther V, et al. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand Suppl. 1994 ; 382: 11-15
23. Fujii A, Yasui-Furukori N, Sugawara N, et al. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010 ; 34: 288-293
24. Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry. 2011 ; 53: 128-133
25. Hägg S, Lindblom Y, Mjörndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol. 2006 ; 21: 93-98
26. Hanssens L, De Hert M, Kalnicka D, et al. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol. 2007 ; 22: 43-49
27. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009 ; 166: 345-353
28. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res. 2002 ; 55: 277-284
29. Iqbal SP, Khan RA, Ahmer S. Antipsychotic treatment and weight gain: Does risperidone behave differently in Pakistani psychiatric patients?. J Ayub Med Coll Abbottabad. 2011 ; 23: 66-69
30. Jerrell JM, McIntyre RS. Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Hum Psychopharmacol. 2007 ; 22: 361-364
31. Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol. 2008 ; 23: 283-290
32. Jerrell JM, Hwang TL, Livingston TS. Neurological adverse events associated with antipsychotic treatment in children and adolescents. J Child Neurol. 2008 ; 23: 1392-1399
33. Jerrell JM, McIntyre RS, Tripathi A. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. Clin Schizophr Relat Psychoses. 2010 ; 4: 161-168
34. Kelly DL, McMahon RP, Liu F, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: A retrospective cohort study. J Clin Psychiatry. 2010 ; 71: 304-311
35. Kendall T. The rise and fall of the atypical antipsychotics. Br J Psychiatry. 2011 ; 199: 266-268
36. Khanna P, Komossa K, Rummel-Kluge C, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013 ; 2: CD006569
37. Khawaja MY. Sexual dysfunction in male patients taking antipsychotics. J Ayub Med Coll Abbottabad. 2005 ; 17: 73-75
38. Khazaal Y, Frésard E, Zimmermann G, et al. Eating and weight related cognitions in people with schizophrenia: A case control study. Clin Pract Epidemiol Ment Health. 2006 ; 2: 29
39. Kobylecki CJ, Jakobsen KD, Hansen T, et al. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: A retrospective matched case-control study. Neuropsychobiology. 2009 ; 59: 222-226
40. Krane-Gartiser K, Breum L, Glümrr C, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry. 2011 ; 65: 345-352
41. Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry. 2004 ; 19: 415-422
42. Laursen TM, Wahlbeck K, Hällgren J, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One. 2013 ; 8: e67133
43. Le Noury J, Khan A, Harris M, et al. The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: Two cohorts, 1875-1924 & 1994-2006 compared. BMC Psychiatry. 2008 ; 8: 67
44. Lencz T, Malhotra AK. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci. 2009 ; 11: 405-415
45. Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009a ; 14: 429-447
46. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013 ; 382: 951-962
47. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet. 2009b ; 373: 31-41
48. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet. 2012 ; 379: 2063-2071
49. Leung SK, Ungvari GS, Ng FS, et al. Tardive dyskinesia in Chinese inpatients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003 ; 27: 1029-1035
50. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry. 1998 ; 43: 596-604
51. MacFarlane IA, Gill GV, Finnegan D, et al. Diabetes in a high secure hospital. Postgrad Med J. 2004 ; 80: 35-37
52. Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: A preliminary study. J Clin Psychiatry. 2005 ; 66: 1386-1391
53. Mackin P, Bishop DR, Watkinson HM. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry. 2007a ; 7: 28
54. Mackin P, Bishop D, Watkinson H, et al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry. 2007b ; 191: 23-29
55. McCann TV, Clark E, Lu S. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. J Adv Nurs. 2009 ; 65: 534-543
56. McIntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med. 2008 ; 162: 929-935
57. Morrato EH, Newcomer JW, Allen RR, et al. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: A retrospective, population-based study of Medicaid claims data. J Clin Psychiatry. 2008 ; 69: 316-322
58. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996 ; 37: 68-73
59. Muzyk AJ, Rayfield A, Revollo JY, et al. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Drug Saf. 2012 ; 35: 547-553
60. Okumura Y, Ito H, Kobayashi M, et al. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: A nationwide retrospective cohort study. Schizophr Res. 2010 ; 119: 145-152
61. Pallava A, Chadda RK, Sood M, et al. Metabolic syndrome in schizophrenia: A comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India. Nord J Psychiatry. 2012 ; 66: 215-221
62. Patel NC, Hariparsad M, Matias-Akthar M, et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol. 2007 ; 17: 303-311
63. Philippe A, Vaiva G, Casadebaig F. Data on diabetes from the French cohort study in schizophrenia. Eur Psychiatry. 2005 ; 20: S340 - S344
64. Reist C, Mintz J, Albers LJ, et al. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: An observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007 ; 27: 46-51
65. National Audit of Schizophrenia. Report of the National Audit of Schizophrenia 2012. Royal College of Psychiatrists ; 2012 :
66. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2010 ; 123: 225-233
67. Saari K, Koponen H, Laitinen J, et al. Hyperlipidemia in persons using antipsychotic medication: A general population-based birth cohort study. J Clin Psychiatry. 2004 ; 65: 547-550
68. Schorr SG, Slooff CJ, Bruggeman R, et al. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res. 2009 ; 43: 1106-1111
69. SIGN 131 (2013) Management of schizophrenia. Available at: www.sign.ac.uk.
70. Smith DJ, Langan J, McLean G, et al. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: Cross-sectional study. BMJ Open. 2013 ; 3: e002808
71. Taylor D, Paton C, Kapur S Maudsley Prescribing Guidelines in Psychiatry. 2012 ) Maudsley Prescribing Guidelines in Psychiatry, 11th ed. Wiley Blackwell. Wiley Blackwell ; 2012 :
72. Taylor M, Shajahan P, Lawrie S. Comparing the use and discontinuation of antipsychotics in clinical practice - an observational study. J Clin Psychiatry. 2008 ; 69: 240-245
73. Taylor D, Young C, Mohamed R, et al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol. 2005 ; 19: 182-186
74. Tsan JY, Stock EM, Gonzalez JM, et al. Mortality and guideline-concordant care for older patients with schizophrenia: A retrospective longitudinal study. BMC Med. 2012 ; 10: 147
75. van Harten PN, Hoek HW, Matroos GE, et al. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: The Curaçao extrapyramidal syndromes study V. J Clin Psychiatry. 2006 ; 67: 1920-1927
76. Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008 ; 22: 238-243
77. Whitaker A, Rao U. Neuroleptics in pediatric psychiatry. Psychiatr Clin North Am. 1992 ; 15: 24376
78. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. J Clin Psychiatry. 2010 ; 71: 463-474
79. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: Therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol. 2011 ; 7: 9-37